The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
April 26th 2024
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Sabizabulin Yields Encouraging rPFS, Tolerable Toxicity Profile in Previously Treated mCRPC
The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).
IS-002 Improves Prostate Cancer Visualization Prior to Robotic Prostatectomy
The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.
Darolutamide Added to ADT/Docetaxel Shows No Increased Toxicity in mHSPC
May 16th 2022The combination of darolutamide plus androgen deprivation therapy and docetaxel presents adverse effects that are similar to those experienced with ADT plus docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Positive Harm-Benefit Data Found in PSA Screening for Black Patients With Prostate Cancer
Complementary approaches to quantifying overdiagnosis generated a more beneficial harm-benefit tradeoff of prostate-specific antigen screening, compared with previous estimates that used shorter follow-up from the introduction of screening.
Darolutamide Maintains OS Benefit in Castration-Resistant Prostate Cancer
May 14th 2022Darolutamide elicited consistent benefits in overall survival and prostate-specific antigen outcomes, irrespective of prior local therapy with radiotherapy or radical prostatectomy, in patients with nonmetastatic castration-resistant prostate cancer.
Relugolix Shows Acceptable Safety in Patients With Advanced Prostate Cancer Enrolled to HERO Trial
Results from a detailed safety analysis of the pivotal phase 3 HERO trial showed that relugolix, an oral gonadotropin-releasing hormone receptor antagonist, had an acceptable toxicity profile with favorable tolerability in patients with advanced prostate cancer.
Enzalutamide/ADT Shows Long-Term Survival Benefit in mHSPC Regardless of Prior Local Treatment
Enzalutamide added to androgen deprivation therapy demonstrated a benefit in overall survival, radiographic progression-free survival, undetectable prostate-specific antigen rates, objective response rates, and other end points vs placebo/ADT in patients with metastatic hormone-sensitive prostate cancer regardless of whether or not they received prior local therapy.
ARAFOR Data Reveal Favorable Safety, Tolerability With Long-Term Darolutamide Exposure in mCRPC
Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.
Niraparib Plus Abiraterone Acetate/Prednisone Achieves Responses in HRR Gene–Altered mCRPC
The addition of niraparib to abiraterone acetate and prednisone achieved for promising response rates in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.
Novartis Suspends Production of Radioligand Therapy Agents in New Jersey and Italy
Pharmaceutical giant Novartis has temporarily halted radioligand therapy production at sites in Millburn, New Jersey, and Ivrea, Italy, citing potential quality issues in its manufacturing processes.
Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer
Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.
The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden in patients with metastatic castration-sensitive prostate cancer enrolled to the phased 3 TITAN trial.
FDA Grants Priority Review to Darolutamide/Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.